NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Monday, September 9 th at 8:00 a.m. ET to provide an update on its Graves’ Disease (GD) program. The update will consist of new epidemiologic data characterizing the potentially addressable market, additional results from the Phase 2 study of batoclimab,...